DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Hypomethylating agent
Hypomethylating agent
214120Orig1s000
Download
Expression of Genes by Hypomethylating Agents
Epigenetics in Clinical Practice: the Examples of Azacitidine and Decitabine in Myelodysplasia and Acute Myeloid Leukemia
Biological Heterogeneity of Chondrosarcoma: from (Epi) Genetics Through Stemness and Deregulated Signaling to Immunophenotype
Download
Demethylation and Upregulation of an Oncogene Post Hypomethylating Treatment
A Phase II Study of Omacetaxine (OM) in Patients with Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure 2013-0870
Immunotherapy of MDS: You Can Run, but You Can’T Hide
New Strategies in Acute Myeloid Leukemia: Redefining Prognostic Markers to Guide Therapy
How We Treat Higher-Risk Myelodysplastic Syndromes
Eunethta Joint Action 3 WP4 VENETOCLAX with a HYPOMETHYLATING AGENT for the TREATMENT of ADULT PATIENTS with NEWLY DIAGNOSED
Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide Ephraim Joseph Fuchs
Mutation Allele Burden Remains Unchanged in Chronic
Antiproliferative and Antitumor Effects of Azacitidine Against the Human Myelodysplastic Syndrome Cell Line SKM-1
The Mtor Inhibitor Everolimus in Combination with Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia: a Phase Ib/II Study
Hypomethylating Agent Induction Therapy Followed by Hematopoietic Cell Transplantation Is Feasible in Patients with Myelodysplastic Syndromes
Novel Drugs for Older Patients with Acute Myeloid Leukemia
Top View
Venclyxto, INN-Venetoclax;
Epigenetics and Chemoresistance in Colorectal Cancer: an Opportunity
Polo-Like Kinase Inhibition As a Therapeutic Target in Acute Myeloid Leukemia
Establishment of Drug-Resistant Cell Lines As a Model in Experimental
Novel Combination Strategies for Older Adults with Advanced MDS and AML
© Ferrata Storti Foundation
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Next-Generation Hypomethylating Agent SGI-110 Primes Acute Myeloid Leukemia Cells to IAP Antagonist by Activating Extrinsic and Intrinsic Apoptosis Pathways
Exposure Time Versus Cytotoxicity for Anticancer Agents
Combination Strategies for the Treatment of KRAS Mutant Colorectal and Pancreatic Cancer by Joel D. Maust a Dissertation Submitt
Activation of Expressïon of P15, P73 and E-Cadherin in Myeloid Leukemia Ceils by Dïfferent Concentrations of 5-Aza-2’-Deoxycytid I Ne
Pharmacokinetic-Pharmacodynamic Studies of 5-Azacytidine in Combination with Gti2040
An Open-Label, Phase II Multicohort Study of an Oral Hypomethylating
Hypomethylating Agents (HMA) for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes: Mechanisms of Resistance and Novel HMA-Based Therapies
How I Treat MDS After Hypomethylating Agent Failure
Emerging Treatment Options for Myelodysplastic Syndromes
Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure
DNA Hypomethylating Drugs in Cancer Therapy
Physicians' Cancer Chemotherapy Drug Manual 2015
Core Submission Dossier
Recent Advances in the Cellular and Molecular Understanding of Myelodysplastic Syndromes: Implications for New Therapeutic Approaches
Treating the Patient with High-Risk MDS: Practical Strategies and Emerging Therapeutic Options
Exploring the Epigenetic Drug Discovery Landscape
Hypomethylating Chemotherapeutic Agents As Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
Phase I Clinical Trials VOLUME 6, NO
The Emergence of Drug Resistance to Targeted Cancer Therapies Clinical
Targeting PI3K/Akt/Mtor in AML: Rationale and Clinical Evidence
P53-Inducible Ribonucleotide Reductase (P53r2/RRM2B) Is a DNA Hypomethylation–Independent Decitabine Gene Target That Correlat
WO 2018/223002 Al 06 December 2018 (06.12.2018) W ! P O PCT
Small Molecules As Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma
Phase I Clinical Trials VOLUME 8, NO
Deoxycytidine (Decitabine) in the Design of Its Dose-Schedule for Cancer Therapy
The Wolf of Hypomethylating Agent Failure
A Role for DNA Mismatch Repair in Sensing and Responding to Fluoropyrimidine Damage
Role of CK2 Inhibitor CX-4945 in Anti-Cancer Combination Therapy – Potential Clinical Relevance
Advances in LLM
Resistance to Decitabine and 5-Azacytidine Emerges from Adaptive Responses of The
Characterization of Newly Established Pralatrexate-Resistant Cell Lines and the Mechanisms of Resistance
Pack-Inserts.Pdf
WO 2017/106656 Al 22 June 2017 (22.06.2017) W P O P C T
A Phase Ib/Iib, Open-Label, Multi-Center Study of Oral
Clinical Effects of Hypomethylating Agents in Patients with Newly
United States Securities and Exchange Commission Form
Hypomethylating Agents in the Treatment of Acute Myeloid Leukemia: a T Guide to Optimal Use ⁎ Valeria Santinia, Gert J
Haematol.2018.214882.Full